06160 BEIGENE
- 103.600
- +1.700+1.67%
BEIGENE News
Wall Street bosses are optimistic about China Securities! Not only Bank of America and Temasek, but also these star funds have greatly increased their positions
① In the first quarter of this year, many foreign-funded institutions bought Chinese securities or related ETFs in a big way, showing their confidence in China's asset prospects; ② Chinese internet giants such as Pinduoduo, Ali, JD, and Baidu became their favorite targets.
BeiGene (06160) grants share options to subscribe for a total of 12,000 American Depositary Shares under the 2016 Options and Incentive Plan
BeiGene (06160) issued an announcement. On May 10, 2024, the Remuneration Committee of the Board of Directors was based on 201...
BeiGene (06160.HK): Grant of share options and restricted share units
Glonghui, May 16, 丨 BeiGene (06160.HK) issued an announcement. On May 10, 2024, the Board's Remuneration Committee granted 4 grantees the right to subscribe for a total of 11,800 American Depositary Shares and granted restricted share units involving a total of 7027 million American Depositary Shares to 164 grantees in accordance with the terms of the 2016 Options and Incentive Plan.
The top four private equity firms revealed the “US stock report card”: Pinduoduo is still proud of Gao Yi and Gao Yi, but Jing Lin quietly reduced its positions
① The latest moves by Chinese private equity institutions such as Gao Yi, Gao Yi, Jing Lin, and Himalaya have recently been revealed; ② Overall, Chinese securities are still popular among Chinese institutions, especially Pinduoduo, and are also famous in the leading positions of Gao Yi, Gao Yi, and Jing Lin; ③ However, Jing Lin drastically reduced its holdings of Pinduo by 1.1 million shares in the first quarter, which is at odds with Gao Yu and Gao Yi's move to increase positions.
I made a double profit! The two giants simultaneously increased their holdings in Pinduoduo, and Gao Lin weighed nearly 10 billion yuan
With the successive disclosure of the US Stock 13F Report, private equity giants' latest positions have surfaced.
BeiGene Performance Analysis: A Hold Rating With Cautious Optimism Amidst Competitive Pressures
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
Express News | BeiGene BTK inhibitor Baiyueze approved for follicular lymphoma indications in China
BeiGene (688235): Strong performance, rapid dosage of zebutinib
The company released its 2023 annual report and 2024 quarterly report: 2023 revenue of 17.4 billion yuan, +82% year-on-year; net loss to mother was 6.7 billion yuan, a year-on-year decrease. 2024Q1 revenue of 5.4 billion yuan, +75% year over year
BeiGene (688235): Zebutinib's global sales pipeline exceeds expectations and is actively advancing
1Q24 results slightly exceeded our expectations The company announced 1Q24 results: revenue of US$752 million (+68% YoY), net loss to mother of US$251 million, product revenue slightly exceeding expectations and reasonable cost control, revenue and
BeiGene (688235.SH): Revenue exceeded 5 billion yuan in the first quarter, accelerating differentiated innovation
On May 8, BeiGene (688235)'s US stock performance report for the 2024 Q1 quarter and the A-share performance report were freshly released. Financial reports show that during the reporting period, BeiGene's total revenue reached 5.359 billion yuan, up 74.8% year on year; thanks to the rapid release of the two core self-developed products, the company's global product revenue reached 5.325 billion yuan, up 89.6% year on year and 17.8% month on month, exceeding market expectations. At the same time as revenue increased dramatically, thanks to strict expense management, BeiGene's operating expenses grew slowly. Current sales and management expenses accounted for 8 percent of product revenue compared to the same period last year
BeiGene Shenzhou Co., Ltd. 2024 First Quarter Report
BeiGene (688235.SH)'s first quarter revenue surged 74.8% to 5.359 billion yuan, R&D investment increased 18.1% to 3.328 billion yuan
BeiGene (688235.SH) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Express News | BeiGene: Net profit loss of 1.908 billion yuan in the first quarter of 2024
Express News | BeiGene: Multiple pipelines are expected to enter clinical trials. Product revenue is expected to continue to grow in 2024
BeiGene's Soaring Sales and Path to Profitability Reinforce Buy Rating
Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Is Maintained at Buy by TD Cowen
TD Cowen: Maintaining the BGNE.US (BGNE.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $236.00 to $254.00.
TD Cowen: Maintaining the BGNE.US (BGNE.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $236.00 to $254.00.
Analysis
Price Target
No Data
